Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide.


Journal Article

The combination of cisplatin, doxorubicin, and cyclophosphamide was used to treat 28 patients with recurrent and metastatic cervical cancer. Five patients had a complete response and one patient had a partial response, yielding a total response rate of 21%. Eleven patients had stable disease. The median survival for the whole group was 42 weeks. Responders had a statistically significant prolongation of survival at a median of 113 weeks (P less than 0.01). There was no statistically significant difference in progression-free interval between responders and patients with stable disease. The overall median progression-free survival was 26 weeks. The toxicities noted were primarily nausea, vomiting, and myelosuppression. The combination of cis-platin, doxorubicin, and cyclophosphamide has modest effectiveness in the treatment of metastatic or recurrent carcinoma of the cervix.

Full Text

Duke Authors

Cited Authors

  • Hoffman, MS; Roberts, WS; Bryson, SC; Kavanagh, JJ; Cavanagh, D; Lyman, GH

Published Date

  • January 1988

Published In

Volume / Issue

  • 29 / 1

Start / End Page

  • 32 - 36

PubMed ID

  • 3338661

Pubmed Central ID

  • 3338661

International Standard Serial Number (ISSN)

  • 0090-8258

Digital Object Identifier (DOI)

  • 10.1016/0090-8258(88)90143-6


  • eng

Conference Location

  • United States